bisphosphonate + teriparatide + denosumab

This entry refers to a combination or therapeutic regimen involving three distinct classes of osteoporosis medications: bisphosphonates, teriparatide, and denosumab. Bisphosphonates (such as alendronate, risedronate, or zoledronic acid) are small molecules that inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase. Teriparatide is a recombinant human parathyroid hormone (1-34) that acts as an anabolic agent, stimulating osteoblast activity and bone formation via the parathyroid hormone receptor 1. Denosumab is a human monoclonal antibody that binds to and neutralizes RANKL (RANK ligand), thereby preventing the maturation and activity of osteoclasts. These agents are often studied or used sequentially or in combination to treat severe osteoporosis, particularly in patients where renal function is a concern. The specific context provided relates to an observational study (NCT02644330) led by Toshihiko Kono investigating the relationship between these osteoporosis medications and residual renal function.

Other names

Bis + teriparatide + denosumab